Loading stock data…
Precipio (PRPO)
$27.25-0.15 (-0.55%)
Market ClosedLast close Sep 8
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Precipio, Inc. in the Healthcare sector is trading at $27.25 with a market capitalization of $40M. The stock is currently 19% below its 52-week high of $33.63, remaining 8.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.71M↑ | $6.70M↓ | $6.77M↑ | $5.65M↑ | $4.93M |
| Gross Profit | $2.73M↓ | $3.13M↑ | $3.00M↑ | $2.43M↑ | $2.14M |
| Operating Income | -$1.43M↓ | $542,000↑ | -$61,000↑ | -$824,000↑ | -$859,000 |
| Net Income | -$1.44M↓ | $526,000↑ | -$79,000↓ | $74,000↑ | -$884,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagn...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$40.11M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.51%
Volume
Today's trading volume
304,054
Recent News
PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
Precipio and Biodesix take different approaches to cancer diagnostics, but which stock looks more compelling now? Let's dive in.
Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong
PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...
Precipio Inc (PRPO) surpasses $7 million in quarterly revenue, achieves positive adjusted EBITDA, and generates strong operating cash flow.
Precipio, Inc. Q2 2026 Earnings Call Summary
Moby summary of Precipio, Inc.'s Q2 2026 earnings call
PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?
Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in.